Novartis Pharma (encorafenib (LGX818)) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Novartis Pharma (encorafenib (LGX818)) General Information

Description

A key protein kinase in the RAS/RAF/MEK/ERK signaling pathway. It regulates several key cellular activities including proliferation, differentiation, migration, survival and angiogenesis.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Other Business Products and Services
Acquirer
Corporate Office
  • Boulder, CO
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Novartis Pharma (encorafenib (LGX818)) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Novartis Pharma (encorafenib (LGX818))‘s full profile, request access.

Request a free trial

Novartis Pharma (encorafenib (LGX818)) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Novartis Pharma (encorafenib (LGX818))‘s full profile, request access.

Request a free trial

Novartis Pharma (encorafenib (LGX818)) FAQs

  • Where is Novartis Pharma (encorafenib (LGX818)) headquartered?

    Novartis Pharma (encorafenib (LGX818)) is headquartered in Boulder, CO.

  • What industry is Novartis Pharma (encorafenib (LGX818)) in?

    Novartis Pharma (encorafenib (LGX818))’s primary industry is Buildings and Property.

  • Is Novartis Pharma (encorafenib (LGX818)) a private or public company?

    Novartis Pharma (encorafenib (LGX818)) is a Private company.

  • What is Novartis Pharma (encorafenib (LGX818))’s current revenue?

    The current revenue for Novartis Pharma (encorafenib (LGX818)) is 000000.

  • Who are Novartis Pharma (encorafenib (LGX818))’s investors?

    Novartis has invested in Novartis Pharma (encorafenib (LGX818)).

  • When was Novartis Pharma (encorafenib (LGX818)) acquired?

    Novartis Pharma (encorafenib (LGX818)) was acquired on 02-Mar-2015.

  • Who acquired Novartis Pharma (encorafenib (LGX818))?

    Novartis Pharma (encorafenib (LGX818)) was acquired by Array BioPharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »